Metastatic Tumor Research and Outcomes Network

Condition(s) studied

Study summary

The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).

Eligibility

Primary outcome measure(s)

• Patient details — collected at baseline
  The following patient data will be collected: * gender, year of birth, height, weight, race * work status, education level, marital status * smoking, alcohol and recreational drug use * medication use * nutrition and vitamin intake * presence of osteoporosis * comorbidities according to the Charlson Comorbidity Index - CCI
• Tumor details — collected at baseline, first prospective treatment and follow-up
  Primary cancer * Site of the primary cancer * Year of diagnosis * Status of the tumor (removed completely, partially, or not removed) * Signs of local control or tumor progression * Tumor subtype * Tumor markers Spine metastases * Date of initial diagnosis of spine metastases * Identification of index target * Vertebral location (i.e., C1, T3-T5, etc.) * Details of spine metastases and other metastases, if any * Activity of systemic metastases * Local control of metastatic tumor * Presence of pathologic fracture * Radiographic evidence of new spine metastatic disease
• Symptoms — collected at baseline, first prospective treatment and follow-up
  For patients with metastatic spine tumor, it is important to understand the occurrence, location, and type of pain patients have at baseline and at follow-up visits. Pain symptoms assessed by the physician will therefore be collected in addition to the pain specific PROs. Bowel and bladder function will be assessed by the physician.
• Treatment details - previous treatment of the index of the spine — Collected at baseline
  If the patient had previous treatment (surgery, radiation or systemic oncologic therapy) for the index target, the following information about the previous treatment will be collected at baseline: * Type(s) of treatment * Date(s) of treatment * Treated vertebrae level(s) * Procedure details * Hospital/center where the treatment was administered * ASIA impairment scale (applies only to previous surgical patients)
• Imaging information — collected at baseline, first prospective treatment, discharge and at follow-up.
  Skeletal muscle and adipose tissue measurements will be made from CT scans. One transverse CT image of the inferior surface of L3 will be assessed by an independent assessor to calculate the visceral fat area to subcutaneous fat ratio (VFA/SFA ratio). This measurement will only be collected if the CT scan is according to standard of care and the method is described in a separate imaging manual. Additional CT scans will not be performed for this Registry. Imaging is critical to select the biopsy technique and for disease diagnosis. Follow-up imaging also plays an important role in monitoring disease status. Imaging data will be collected to serve as a data repository, so that images may be more easily retrieved later if necessary. Imaging data * Image type (e.g. MRI, CT, PET, etc.) * Date taken * Name of institution storing image
• Patient reported outcomes - Euroqol EQ-5D-3L / - EQ-5D VAS — collected at baseline, first prospective treatment, discharge and at follow-up.
  The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
• Ambulation — collected at baseline, discharge and at follow-up.
  Details about the ability of the patient to walk, cause of ambulation loss, use of an assistive device, and timing will be collected. 10 meter walk test (10 MWT) If the patient is able to ambulate without physical assistance (i.e. without help of a person), ambulation will be assessed by the 10MWT (walking aids are allowed). The 10MWT evaluates the time required to walk 10 meters. Patients should walk 10 meters with 2 meters for acceleration and deceleration. The patient will be timed from when the patient's toes of the leading foot cross the 2 meter line to when the patient's toes of the leading foot cross the 8 meter line. The test should be performed three times and the results will be averaged. The patient should be instructed to perform the test at a comfortable walking pace.
• Nutritional status tool — collected at baseline, first prospective treatment, discharge and at follow-up.
  The Scored Patient-Generated Subjective Global Assessment (PG-SGA©) sets the standard of and is the preeminent interdisciplinary patient assessment (weight, intake, symptoms, functional status, disease state, metabolic stress and nutritional physical examination) in oncology and other chronic catabolic conditions. The Scored PG-SGA© includes the four patient-generated historical components ('Weight History', 'Food Intake', 'Symptoms' and 'Activities and Function'), the professional part (Diagnosis, Age, Metabolic stress, and Physical Exam), the Global Assessment (A = well nourished, B = moderately malnourished or suspected malnutrition, C = severely malnourished), the total numerical score, and nutritional triage recommendations. Subsequently, the Scored PG-SGA© allows for triaging of specific nutrition interventions, as well as facilitating quantitative outcomes data collection. This assessment is available in a variety of languages and as a metric as well as a non-metric version.
• Morbidity data - Adverse events — collected at first prospective treatment, discharge and at follow-up.
  * related to surgery Intra- and postoperative complication data will be recorded for all surgically treated patients during the standard of care scheduled follow-up visits. Complications will be assessed by evaluating the patient's medical files from the time treatment was initiated until the day of follow-up. The Spine AdVerse Events Severity system, version 2 (SAVES V2) AE abstraction tool will be used to record the morbidity data. * related to radiation and/or systemic oncologic therapy For patients treated with RT and/or systemic oncologic therapy, complications and severity grade related to the treatment will be recorded during the standard of care scheduled follow-up visits according to a predefined list: The predefined list and severity grading system are according to the National Cancer Institute Guidelines.
• Local disease recurrence data — collected at baseline and at follow-up.
  At every FU visit, each patient, regardless of which stage they are at in their treatment, will be evaluated for local disease control. Presence or absence of local control and distant metastases should be confirmed through imaging. The timing of the assessment will be performed in accordance with local standard of care scheduled FU visits.
• Survival — collected at first prospective treatment, discharge and at follow-up.
  FU visits will be scheduled and performed according to the local standard of care and at each scheduled visit the patient's survival will be documented. In case a patient misses a scheduled visit it will be assessed if the patient is still alive.
• Treatment details - Current treatment of the index target of the spine — collected at first prospective treatment and at follow-up.
  Since there is a spectrum of different treatment options and combinations for patients with a metastatic spine tumor, detailed information about the three main treatment options (surgery, radiation, and systemic oncologic therapy) for the index target will be collected. The treatment intent, including administration (primary, neo-adjuvant, and adjuvant) will also be collected.
• Treatment details - Current treatment for the primary cancer — collected at baseline, first prospective treatment and at follow-up.
  Information on the status of the primary cancer as well as on ongoing treatment of the primary cancer will be collected at baseline and at follow-up.
• Patient reported outcomes - Pain Numeric Rating Scale — collected at baseline, first prospective treatment, discharge and at follow-up.
  The Pain NRS is an 11-point scale where the end points are the extremes of no pain (0 points), or worst imaginable pain (10 points). It measures subjective intensity of pain and the patient rates his/her overall or average daily pain.
• Patient reported outcomes - Spine Oncology Study Group Outcome Questionnaire (SOSGOQ) — collected at baseline, first prospective treatment, discharge and at follow-up.
  This is a new HRQOL outcome tool which was developed specifically for metastatic spine tumor. It is currently available in English and Hungarian. It contains 20 items representing all four domains of the International Classification of Function and Disability. Additionally there are seven follow-up questions referring to treatment satisfaction. It is made up of five domains: physical function, neural function, pain, mental health and social function. It was developed as a comparison to the SF-36 for patients with spine tumors.

Trial sites (24)